Sign In
Buy VCYT
$48.69
+0.89 (+1.86%)
At Close: Jun 03, 2026
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
11:01am, Thursday, 23'rd May 2024
Veracyte's (VCYT) new studies leverage Afirma GRID's whole-transcriptome approach to uncover novel molecular signatures and alterations.
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
09:41am, Thursday, 23'rd May 2024
We have narrowed our search to five Medical Instruments stocks with strong potential for 2024. These stocks are: ALC, RXST, HOLX, VCYT, MASI.
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
04:05pm, Wednesday, 22'nd May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer.
Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue?
11:00am, Tuesday, 21'st May 2024
Investors are optimistic about Veracyte (VCYT) led by strength in the testing business and upbeat guidance.
Veracyte, Inc. (NASDAQ:VCYT) Shares Sold by Swiss National Bank
04:42am, Monday, 20'th May 2024
Swiss National Bank trimmed its stake in shares of Veracyte, Inc. (NASDAQ:VCYT – Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Secur
Veracyte to Participate in Upcoming Investor Conferences
05:04pm, Wednesday, 15'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences. Leerink Par
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade
11:01am, Monday, 13'th May 2024
The mean of analysts' price targets for Veracyte (VCYT) points to a 39.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View
09:56am, Wednesday, 08'th May 2024
Veracyte's (VCYT) first-quarter 2024 performance reflects the strength of its testing business.
Veracyte Announces First Quarter 2024 Financial Results
04:05pm, Tuesday, 07'th May 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. “We had a strong start to 2024, driven by ro
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients.
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
05:00pm, Monday, 22'nd Apr 2024
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, M
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines.
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
03:20pm, Monday, 26'th Feb 2024
While biotech stocks offer some of the most pertinent ideas available in the market, they can be awfully risky. One bad clinical result and boom – there goes your hard-earned money in the toilet.
